- Providers
- Life Sciences
- Breast
- AI
- Conference
San Antonio Breast Cancer Symposium
Join Tempus at SABCS® 2026 as we showcase groundbreaking clinical research and our latest AI-powered technology—all designed to drive more informed R&D and personalized care across the breast cancer patient journey.
Experience live demos of our newest technologies for providers, biopharma, and research partners.
Experience live demos of our AI-enabled technologies for clinicians, biopharma, and researchers
Tempus Hub
Streamline ordering and get quick access to patient information through our secure AI-enabled platform. Place orders tailored to your patient’s diagnosis, view comprehensive smart reports, get AI-generated summaries at a glance, receive automatic therapy match updates when new options emerge, and review patient medical history—all on one intelligent platform.
Tempus One
Leverage your co-pilot in Hub to get real-time answers and uncover patient insights fast. Just ask a question to access data-driven responses, draft documents like prior authorizations, review up-to-date clinical trial information, and so much more.
Tempus Lens
Quickly find, access, and analyze multimodal de-identified data records and uncover critical insights to accelerate research and innovation. Leverage our Al assistant, Tempus One, to quickly define detailed patient cohorts using natural language processing and transform complex criteria into actionable datasets in seconds. Explore unstructured clinical data and extract nuanced insights.
Distinct Mutational and Immunologic Profiles in HR+/HER2-negative Early-Onset Breast Cancer: Results from a Large Clinico-Genomic Database
Type: Poster
Presentation Number: P1-2-24 (Abstract #1650)
Description: (coming soon)
Nerea Lopetegui-Lia, et al.
Suz12-low invasive lobular carcinoma defines a receptor-subtype-independent molecular subgroup: a real-world multimodal analysis
Type: Poster
Presentation Number: P1-9-28 (Abstract #3116)
Description: (coming soon)
B. Al-Zubeidy, et al.
Genomic and immunologic landscape of triple-negative breast cancer by age: A comprehensive analysis of over 3,000 patients
Type: Poster
Presentation Number: P1-5-04 (Abstract #958)
Description: (coming soon)
A. LeVee, et al.
Sequencing of PARP Inhibitors and Trastuzumab Deruxtecan in BRCA1/2/PALB2-Altered, HER2-Negative Metastatic Breast Cancer: A Retrospective Study from the Nationwide De-Identified Tempus Database
Type: Poster
Presentation Number: P1-6-14 (Abstract #827)
Description: (coming soon)
N. Zeltser, et al.
HER2 RNA Outperforms IHC in Predicting Outcomes to T-DXd
Type: Poster
Presentation Number: P1-5-27 (Abstract #1689)
Description: (coming soon)
J. Bell, et al.
Real-world detection, molecular characterization, and clinical implications of emerging ESR1 mutations (ESR1m) during first-line (1L) treatment of hormone receptor–positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC)
Type: Poster
Presentation Number: P2-5-21 (Abstract #365)
Description: (coming soon)
Jason A. Mouabbi, MD, et al.
Immune profile score (IPS) to stratify outcomes in patients with metastatic triple negative breast cancer (mTNBC) treated with immune checkpoint inhibitors (ICIs)
Type: Poster and Spotlight Discussant Session
Presentation Number: PS13-10 (Abstract #2136)
Description: (coming soon)
Irene M. Kang, et al.
Trastuzumab deruxtecan (T-DXd) versus sacituzumab govitecan (SG) in HER2-low/0 metastatic breast cancer (mBC) by HER2 status and Trop-2 expression
Type: Poster and Spotlight Discussant Session
Presentation Number: PS5-4 (Abstract #683)
Description: (coming soon)
A. LeVee, et al.
Predicting Outcomes and Differential Treatment Benefit in Post-CDK4/6i HR+/HER2- Metastatic Breast Cancer Using Longitudinal EHR Data and a Multimodal Oncology Foundation Model (oFM)
Type: Poster
Presentation Number: P3-3-13 (Abstract #3439)
Description: (coming soon)
Yi Kan Wang, et al.
Timing of Breast Cancer Surveillance: Is the “10-Years Earlier” Rule Appropriate?
Type: Poster
Presentation Number: P3-4-09 (Abstract #3009)
Description: (coming soon)
Magan Trottier, et al.
10 Years in the Making: Genetic Test Results in a Large Male Breast Cancer Cohort in an Evolving Genomic Landscape
Type: Poster
Presentation Number: P3-4-20 (Abstract #3020)
Description: (coming soon)
Mary Pritzlaff, et al.
Real-world outcomes of metastatic invasive lobular carcinoma (mILC) vs. invasive ductal carcinoma (mIDC) treated with PI3K inhibitors
Type: Poster
Presentation Number: P4-14-11 (Abstract #382)
Description: (coming soon)
Natalie K Heater, et al.
Integrating psychiatric pharmacogenomics in breast cancer care: provider perspectives and clinical utilization in patients with comorbid emotional distress
Type: Poster
Presentation Number: P4-4-07 (Abstract #1656)
Description: (coming soon)
Kadie Harry, PhD, et al.
Fragmentomics Enables Actionable Breast Cancer Subtyping on a Commercial Liquid Biopsy Assay
Type: Poster
Presentation Number: P5-4-01 (Abstract #1251)
Description: (coming soon)
Greg Mayhew, et al.
Whole-Genome Sequencing Reveals Distinctive Chromosome 17 Copy Number and Structural Variant Landscapes in Breast Cancer Tissue Samples
Type: Poster
Presentation Number: P5-4-16 (Abstract #1522)
Description: (coming soon)
Brittany Mineo, et al.
Schedule a meeting with us
We'll be in touch shortly.